11 Dec 2019 BioInvent and Transgene announce compelling preclinical data for BT-001 in solid tumors
11 Dec 2019 FDA Accepts Supplemental Biologics License Application for Xolair (Omalizumab) for the Treatment of Nasal Polyps
11 Dec 2019 First patient dosed in BIVV001 phase 3 XTEND-1 study in people with severe haemophilia A
10 Dec 2019 ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting
10 Dec 2019 Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation
10 Dec 2019 MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
10 Dec 2019 CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody
10 Dec 2019 CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
10 Dec 2019 ImmunoGen Presents Updated Findings from Phase 1 Study of IMGN632 at ASH Annual Meeting
10 Dec 2019 Amphivena Reports Data on Phase 1 Study of AMV564 at Ash Annual Meeting
10 Dec 2019 UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
09 Dec 2019 Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting
09 Dec 2019 Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate
09 Dec 2019 Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual Meeting
09 Dec 2019 IONTAS Antibody Enters Clinical Trial for Use in the Treatment of B Cell Acute Lymphoblastic Leukemia
09 Dec 2019 Sesen Bio Initiates Rolling Submission of BLA for Vicinium to FDA
09 Dec 2019 First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
09 Dec 2019 Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis
09 Dec 2019 Immunocore announces dosing of first patient with third ImmTAC® bispecific
08 Dec 2019 Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition
08 Dec 2019 FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
08 Dec 2019 Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma
08 Dec 2019 Genentech Announces New Data on Novel Cd20-cd3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas
08 Dec 2019 ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)
06 Dec 2019 BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up